Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atelectasis22.01.02.0010.000157%
Atrial fibrillation02.03.03.0020.000629%
Atrioventricular block02.03.01.0020.000052%Not Available
Atrioventricular block complete02.03.01.0030.000175%
Atrophy08.03.04.001--Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.000070%Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.0100.000035%Not Available
Azotaemia20.01.01.0010.000070%Not Available
B-cell lymphoma16.28.01.001; 01.15.01.0010.000175%Not Available
Bile duct cancer16.07.01.001; 09.04.02.0010.000052%Not Available
Bladder dilatation20.03.01.0070.000035%Not Available
Blindness06.02.10.003; 17.17.01.0030.000227%Not Available
Blindness transient06.02.10.006; 17.17.01.0040.000052%Not Available
Blindness unilateral06.02.10.007; 17.17.01.0160.000035%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Bone disorder15.02.04.0040.000350%Not Available
Bowen's disease23.08.02.004; 16.03.02.0040.000035%Not Available
Bradycardia02.03.02.002--Not Available
Brain compression17.07.02.0050.000035%Not Available
Brain stem infarction24.04.06.014; 17.08.01.0240.000035%Not Available
Breast enlargement21.05.04.0010.000070%Not Available
Breech presentation18.03.04.0010.000035%Not Available
Bronchiectasis22.03.02.0050.000052%Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.000175%
Bundle branch block left02.03.01.0070.000035%Not Available
Bundle branch block right02.03.01.0110.000087%Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.000035%Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.000594%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene